middle-of-the-night awakening

(redirected from middle-of-the-night insomnia)

middle-of-the-night awakening

Insomnia characterised by a difficulty in returning to sleep once awakened after going to sleep for the night and before getting up at one’s usual time in the morning. MOTN awakening is associated with excessive daytime sleepiness and fatigue.

Frequency
Occurs in one-third of the general population at least three nights/week.

Aetiology
Anxiety, obstructive sleep apnoea, chronic pain, pregnancy, toilet needs, depression, bipolar disorder, obesity, hypertension, heart disease, alcohol consumption, menopause, etc.

Management
No medication is consistently effective.
References in periodicals archive ?
According to the company, the United States Patent and Trademark Office's (USPTO) patent includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem.
It includes claims directed at methods of treating middle-of-the-night insomnia with low doses of zolpidem.
"Patients with middle-of-the-night insomnia now have a treatment option approved for dosing in the middle of the night," said sleep expert, professor of family medicine and associate editor of the Delaware Medical Journal Dr.
Sublingual Zolpidem (Intermezzo), the most recent entry in the class, has a 2.5-hour half-life and can be used for middle-of-the-night insomnia if patients have at least 4 hours left in bed.
AMSTERDAM -- A sublingual 3.5-mg formulation of Zolpidem tartrate is effective for middle-of-the-night insomnia, producing no tolerance, rebound, or increase in use over 4 weeks, investigators reported at the congress.
AMSTERDAM - A sublingual 3.5-mg formulation of Zolpidem tartrate is effective for middle-of-the-night insomnia, producing no tolerance, rebound, or increase in use over 4 weeks, investigators reported.
Major Finding: Persons who received a new formulation of tow-dose sublingual zolpidem for middle-of-the-night insomnia showed no potential for abuse of the drug in the form of dependency, tolerance, or rebound potential, compared with placebo recipients.